Valuation: Evaxion A/S

Market Cap 27.27M 23.74M 22.41M 20.36M 38.15M 2.61B 38.32M 268M 104M 1.33B 102M 100M 4.28B P/E 2026 *
-81.8x
P/E 2027 * -218x
Enterprise Value 27.27M 23.74M 22.41M 20.36M 38.15M 2.61B 38.32M 268M 104M 1.33B 102M 100M 4.28B EV / Sales 2026 *
-
EV / Sales 2027 * 5.84x
Free-Float
58.26%
Yield 2026 *
-
Yield 2027 * -
1 day+1.55%
1 week+4.47%
Current month+9.00%
1 month+3.81%
3 months+7.21%
6 months-13.49%
Current year-31.45%
1 week 3
Extreme 3
3.33
1 month 2.9
Extreme 2.9
3.64
Current year 2.77
Extreme 2.77
5.48
1 year 2.77
Extreme 2.77
12.15
3 years 1.2
Extreme 1.2
68.05
5 years 1.2
Extreme 1.2
1,252
10 years 1.2
Extreme 1.2
1,252
Manager TitleAgeSince
Corporate Officer/Principal 49 2008-08-10
Chief Executive Officer 59 2025-11-23
Director of Finance/CFO 53 2024-10-31
Director TitleAgeSince
Chairman 58 2020-11-24
Director/Board Member 56 2017-12-31
Director/Board Member 68 2021-05-24
Date Insider Type Main position Quantity % Market Cap. Importance
4/16/26 Other

Director

2,376 0.0006%
3/18/26 Other

Chief Financial Officer

645,750 0.1549%
3/18/26 OtherCompany 360,406 0.0864%
Change 5-day change 1-year change 3-year change Capi.($)
+1.55%+4.47%+8.28%-89.07% 27.27M
+0.11%+2.71%+0.33%+28.59% 46.28B
-1.12%+1.78%+40.07%+27.26% 43.85B
-3.04%-6.29%+322.27%+517.36% 40.93B
-0.74%+1.25%+2.32%+67.94% 39.9B
-0.50%+0.67%+11.79%+40.51% 29.5B
-0.46%+4.22%+21.99%+124.21% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.15%+38.93% 15.22B
-3.14%+31.91%-10.60% - 14.05B
Average -0.89%+3.83%+46.51%+94.47% 26.24B
Weighted average by Cap. -1.10%+1.87%+64.68%+130.21%

Financials

2026 *2027 *
Net sales - 4.67M 4.07M 3.84M 3.49M 6.53M 448M 6.56M 45.9M 17.73M 228M 17.54M 17.15M 733M
Net income -15.56M -13.55M -12.79M -11.62M -21.77M -1.49B -21.86M -153M -59.08M -759M -58.45M -57.15M -2.44B -11.81M -10.28M -9.71M -8.82M -16.52M -1.13B -16.6M -116M -44.85M -576M -44.37M -43.39M -1.85B
Net Debt - -
Logo Evaxion A/S
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Employees
46
Date Price Change Volume
26-09-18 US$3.270 +1.55% 43,342
26-09-17 US$3.220 +6.27% 53,340
26-09-16 US$3.030 -0.33% 73,871
26-09-15 US$3.040 -0.98% 11,166
26-09-14 US$3.070 -1.92% 21,870
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.270USD
Average target price
11.25USD
Spread / Average Target
+244.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVAX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!